Prior to L-NMMA infusion (at 70 min) | During L-NMMA infusion (at 130 min) | |
---|---|---|
PWV(m/s) | ||
Placebo | 5.2 ± 0.5 | 5.4 ± 0.5 |
Tolvaptan 15 mg | 5.0 ± 0.5 | 5.4 ± 0.6** |
Tolvaptan 30 mg | 5.2 ± 0.6 | 5.5 ± 0.6 ** |
Tolvaptan 45 mg | 5.2 ± 0.3 | 5.5 ± 0.4** |
p (ANOVA) | 0.518 | 0.851 |
AI | ||
Placebo | −0.7 ± 13.8 | 0.1 ± 15.1 |
Tolvaptan 15 mg | −1.5 ± 12.5 | −1.2 ± 17.3 |
Tolvaptan 30 mg | −0.4 ± 11.8 | 2.5 ± 17.8 |
Tolvaptan 45 mg | −3.3 ± 15.8 | 1.6 ± 12.0* |
p (ANOVA) | 0.968 | 0.961 |
CSBP | ||
Placebo | 97 ± 9 | 100 ± 8** |
Tolvaptan 15 mg | 97 ± 9 | 101 ± 10* |
Tolvaptan 30 mg | 96 ± 9 | 102 ± 9** |
Tolvaptan 45 mg | 96 ± 8 | 102 ± 6** |
p (ANOVA) | 0.989 | 0.952 |
CDBP | ||
Placebo | 63 ± 7 | 68 ± 6*** |
Tolvaptan 15 mg | 63 ± 7 | 68 ± 9** |
Tolvaptan 30 mg | 61 ± 6 | 68 ± 7*** |
Tolvaptan 45 mg | 62 ± 5 | 68 ± 6** |
p (ANOVA) | 0.936 | 0.998 |